Press Release: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Express News | C4 Therapeutics Appoints Paige Mahaney, Ph.d., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.d.
Express News | C4 Therapeutics Announces Presentations and Participation in 7TH Annual Targeted Protein Degradation & Induced Proximity Summit
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Business Is Trailing The Industry But Its Shares Aren't
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley analyst Terence Flynn maintains $C4 Therapeutics(CCCC.US)$ with a hold rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 63.9%
Express News | C4 Therapeutics Inc : Evercore ISI Raises Target Price to $10 From $9
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data
Express News | C4 Therapeutics Inc - Cft1946 Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
Daily options tracking | AI stock Palantir surged 14%, call options made 8 times profit; hedging stock price to drop by the end of September? Tesla sold millions of dollars of call options.
Google's second antitrust case is being tried, with big investors betting over $10 million on put options to short. Tesla's extended volatility has risen for five consecutive trading days, while Nvidia is now facing a large block trade with a multimillion-dollar disagreement between long and short positions.
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Top Premarket Decliners
C4 Therapeutics Shares Are Trading Lower. The Company Announced the Abstract Sharing Clinical Data From Its Ongoing Phase 1 Clinical Trial of CFT1946 in Mutant BRAF V600 Solid Tumors, Was Released in Conjunction With the ESMO Congress 2024.
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024